Loading
GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.
Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1).
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Bladder Urothelial Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma.
In plain words · GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.
GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.
Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems.
No product in this corpus aims at GNA13 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA GNA13: RNA tissue enhanced (bone marrow 136 nTPM); high antibody staining in 11 normal tissues; highest cancer staining thyroid cancer (1 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q14344; CIViC gene GNA13; IntOGen GNA13; Human Protein Atlas GNA13 tissue; Open Targets ENSG00000120063 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Kabouridis P.S. et al, Mol. Cell. Biochem, 1995, "Expression of GTP-binding protein alpha subunits in human thymocytes". Source.
Sources: HGNC HGNC:4381 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14344 (protein name, function text, keywords and locations (REST API)); CIViC gene GNA13 (3 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Burkitt Lymphoma (GraphQL API, CC0)); IntOGen GNA13 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1). Promotes tumour cell invasion and metastasis by activating RhoA/ROCK signalling pathway. Inhibits CDH1-mediated cell adhesion in a process independent from Rho activation. In lymphoid follicles, transmits P2RY8- and S1PR2-dependent signals that lead to inhibition of germinal centre (GC) B cell growth and migration outside the GC niche. Location: Cell membrane; Melanosome; Cytoplasm; Nucleus (UniProt). Locus 17q24.1 (HGNC).
RNA: tissue enhanced (bone marrow 136 nTPM), detected in all normal tissues.
Medium: Appendix, Breast, Bronchus, Caudate, Cerebellum, Cerebral cortex, Cervix, Endometrium.
Medium only: breast cancer, carcinoid, glioma, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GNA13" OR ABSTRACT:"GNA13" OR TITLE:"G protein subunit alpha 13" OR ABSTRACT:"G protein subunit alpha 13" OR TITLE:"Guanine nucleotide-binding protein subunit alpha-13" OR ABSTRACT:"Guanine nucleotide-binding protein subunit alpha-13" OR TITLE:"G13" OR ABSTRACT:"G13" OR TITLE:"MGC46138" OR ABSTRACT:"MGC46138") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GNA13, not a curated reading list.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, CIViC, IntOGen, Diffuse large B-cell lymphoma.